"Alkylating Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
| Descriptor ID |
D000477
|
| MeSH Number(s) |
D27.505.519.124 D27.888.569.035
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Alkylating Agents".
Below are MeSH descriptors whose meaning is more specific than "Alkylating Agents".
This graph shows the total number of publications written about "Alkylating Agents" by people in this website by year, and whether "Alkylating Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1996 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 1 | 2 |
| 2004 | 1 | 2 | 3 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 2 | 4 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alkylating Agents" by people in Profiles.
-
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol. 2024 May; 99(5):836-843.
-
ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells. Oncotarget. 2022; 13:319-330.
-
Current and Emerging Pharmaceutical Therapies for Noninfectious Uveitis. Int Ophthalmol Clin. 2019; 59(1):111-126.
-
Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. Exp Hematol. 2018 11; 67:49-59.e1.
-
Toward personalized treatment in Waldenstr?m macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370.
-
Beyond Alkylating Agents for Gliomas: Quo Vadimus? Am Soc Clin Oncol Educ Book. 2017; 37:175-186.
-
Topographic Quantification of the Transcorneal Electrical Stimulation (TES)-Induced Protective Effects on N-Methyl-N-Nitrosourea-Treated Retinas. Invest Ophthalmol Vis Sci. 2016 09 01; 57(11):4614-24.
-
Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep. 2015 Dec 22; 13(11):2353-2361.
-
Complications related to a cosmetic eye-whitening procedure. Am J Ophthalmol. 2014 Nov; 158(5):967-73.
-
Efficacy of probing with mitomycin-C in adults with primary acquired nasolacrimal duct obstruction. J Ocul Pharmacol Ther. 2013 Apr; 29(3):353-5.